Browse Category: Medical > Therapeutics

Categories

[Search within category]

Alpha1–2-Fucosyltransferase for Enzymatic Synthesis of Alpha1–2-linked Fucosylated Glycans

Researchers at the University of California, Davis have discovered an alpha1–2-fucosyltransferase that efficiently catalyzes the synthesis of alpha1–2-linked fucosylated glycans that can contain different internal glycans.

A Novel ER Beta Ligand Prodrug to Treat MS and Other Neurodegenerative Diseases

Researchers from the Department of Neurology and the Department of Chemistry and Biochemistry at UCLA have developed a novel ERβ ligand prodrug that is structurally designed to more easily cross the blood-brain barrier for treatment of multiple sclerosis.

Inhibitors Of The N-Terminal Domain Of The Androgen Receptor

UCLA researchers under the guidance of Drs. Matthew Rettig and Mike Jung have developed a novel family of therapeutics for use against castration resistant prostate cancer. These drugs have been shown to inhibit the androgen receptor and are unaffected by the most common drug-resistant mutations found in prostate cancer patients.

A Novel Method to Generate Specific and Permanent Macromolecular Covalent Inhibitors

UCSF researchers have invented a novel method to generate covalent macromolecular inhibitors. This strategy allows a peptide inhibitor to bind to its target protein specifically and irreversibly through proximity-enabled bioreactivity.

Therapeutic Vaccine for Chronic Hepatitis B (CHB)

Researchers at the University of California, Davis have developed a therapeutic vaccine capsule against Chronic hepatitis B.

Neutralization Of Oxidation Specific Epitopes To Promote Skeletal Bone Growth

Phospholipids are very abundant molecules in the cell, particularly in regard to the role they play in building blocks for membranes, lipoproteins and extracellular vesicles. They are also intimately involved in cellular signaling and other processes when they undergo oxidation to form various degradation products via a process called lipid peroxidation. These newly generated products are often highly reactive and can form neo-epitopes, designated oxidation-specific epitopes (OSEs). OSEs, including oxidized phospholipids (OxPLs) and malondialdehyde (MDA)-modified amino groups and found on the surface of many cells and can be recognized by the immune system. MDA can be subject to degradation by reactive oxygen species, which can further react with acetaldehyde and endogenous proteins, forming malondialdehyde-acetaldehyde (MAA) adducts. These MAA adducts are immunogenic and have pro-inflammatory properties. Furthermore, circulating levels of antibodies against MAA adducts have been shown to correlate with atherosclerotic disease and implicated in a number of other diseases.

Treatment for Retinal Disease

Researchers at the University of California, Davis have developed a method for exosome treatment of retinal disease.

Use of mutant Kv7.2 channels for anti-epileptic and pain therapies

During seizures or pain-induced inflammation, excess chemical mediators suppress potassium channels mediating neuronal activity and thereby inactivate new generation anti-epileptic drugs and painkillers acting on those channels. The invention describes a gene therapy using a genetically-engineered potassium channel that reduces adverse effects by silencing neuronal hyperactivity while maintaining normal neuronal activity in the presence of chemical mediators to treat epilepsy and pain.

Protein Kinase C Epsilon Small Molecule Inhibitors to Treat Pain, Anxiety, Alcoholism, and Nicotine Addiction

This invention provides new inhibitors to protein kinase C epsilon (PKCε) for the treatment and prophylaxis of various diseases such as pain, anxiety, alcoholism, inflammation, cancer, diabetes, and other conditions.

Engineering the protein corona of a synthetic polymer nanoparticle for broad-spectrum sequestration and neutralization of venomous biomacromolecules

Antivenoms are created by harvesting antibodies from surrogate animals that are exposed to small amounts of specific venom. This process is very costly and sometimes ineffective due to variations even within a single species. The inventors at UCI have developed a broad spectrum antivenom using nanoparticles which absorb and sequester key proteins in the venom.

Antisense Oligonucleotides and Drug Conjugates for Obesity and Diabetes Treatment

The obesity epidemic is an ongoing issue leading to significant economic and social burden, in part due to its role in the development of diabetes. Only three DFA-approved drugs for obesity treatment currently exist, none of which are without significant side effects and risks. Researchers at UCI have developed a DNA-based approach that activates metabolism, to target genes only in the fat and liver, causing increased energy expenditure and weight loss without affecting other organs. These present a viable approach to obesity treatment with minimal side effects in comparison to current drug treatments.

An Antibody to Phospho T3 of Human Huntingtin

Huntington’s disease (HD) is a neurodegenerative genetic disorder caused by abnormal function of mutated Huntingtin protein. The invention uncovers an antibody to a new post-translational modification site that affects human Huntingtin aggregation and pathogenesis of HD.

A Therapeutic Bandage For Treating Venom-Induced Tissue Necrosis

Snakebites affect 4.5 million people a year. Treatments that could save victim’s lives require capable medical facilities, which are not always within reach. Researchers at UCI have developed a therapeutic bandage for treating the tissue necrosis associated with snake bites. The invention can be applied in the field and has the potential to save many lives.

New Drug Formulations For Chemoembolization Treatment

Primary liver cancer is the 12th leading cause of death in the United States. This invention is a novel drug delivery system that involves use of liposomes for the binding of a systemic liver cancer drug. The disclosed formulation can be used as a chemoembolization treatment of hepatocellular carcinoma and liver cancer.

Next-generation broad-spectrum anti-cancer Rad51 inhibitors

This invention describes the design, synthesis and successful evaluation of a panel of novel Rad51 inhibitors to treat a broad spectrum of cancer types.

Antibiotic-Peptide Conjugates With Anti-Microbial Efficiency Against Chronic Infections

The global antibiotics market is projected to reach $44.7 billion in 2020, growing at a CAGR of 2%. They are used for treating a large variety of chronic infections such as tuberculosis, pneumonia, typhoid and foodborne illnesses that present a huge health burden. However, there is an urgent need for new antibiotics as resistant bacterial strains are causing recurrent infections. These resistant strains often derive from dormant cells called persister cells that are not penetrated by antibiotics. Targeting these persister cells will help clear recurrent and antibiotic-resistant infections.

Novel Antiviral Compounds to Treat Enterovirus Infections

Researchers in UCLA Department of Molecular & Medical Pharmacology have used a rapid, live virus assay to develop potent enterovirus inhibitors.

Structure-Based Peptide Inhibitors Of Alpha-Synuclein Aggregation, A Potential Therapeutic For Parkinson's Disease

UCLA researchers in the Department of Biological Chemistry have designed a novel peptide inhibitor that can be used as a therapeutic for Parkinson’s disease.

Combination Treatment to Improve Efficacy of BCL-2 inhibitors for Cancer Treatment

Several blood cancers are characterized by over-expression of BCL-2, a key pro-survival protein that protects against cell death. BCL-2 inhibitors as cancer therapeutics have not demonstrated uniform effectiveness against all cancers and for all patients. The current invention combines drugs to achieve synergistic cytotoxicity against these cancer cells, improving prognosis in terms of relapse and mortality rates.

Hybridoma Producing Antibodies To C1qRp

Individuals with genetic immunodeficiency, as well as patients with HIV, cancer, and those undergoing chemotherapy or high risk surgery, are at increased risk for infection. C1q, an important component of the immune system, is known to enhance phagocytosis (cell ingestion of harmful bacteria or other materials). Scientists at UCI have developed antibodies to the receptor for C1q, C1qRp, to be used as a target for prophylactic treatments in populations at high risk of infection.

Compositions for Enhancing Beta Cell Maturation, Health, and Function

Beta cell failure is the central cause of type-2 diabetes. Researchers at UCI have developed molecules for treating diabetes that target proteins on the surface of beta cells and induce their clustering. This clustering results in an increase in insulin secretion and content and promotion of beta cell maturation. Furthermore, the clustering effect seen with these compositions may promote both proliferation and the reversal of de-differentiation.

An Endogenous Anti-angiogenic Protein (EAP) and its Derivatives for Treatment of Cerebral Cavernous Malformations (CCM)

Cerebral cavernous malformation (CCM) is a neurovascular disease that causes epilepsy and stroke for which there is no medical therapy. It has a prevalence of 5 per thousand in western populations and occurs in familial forms as a consequence of mutations in 3 CCM genes: CCM1/KRIT1, CCM2, CCM3/PCDC10 resulting in the formation of CCMs; mutations in the CCM1/KRIT1 gene account for 40% of the inherited cases. Once identified, CCM patients have a lifetime risk of CCM development and progression with increasing risk of stroke, epilepsy, or neurological impairment. 

New Pathway For Cancer Therapy

The field of oncology has seen dramatic increases in understanding in recent years, but new pathways relevant to cancer biology offer opportunities for the screening of small molecules.

Small Molecule Antagonists Of The Pro-Survival Protein Mcl-1

UCLA Researchers have discovered novel inhibitors to signaling proteins involved in the regulation of apoptosis. MCL-1, which is known to be overexpressed in many cancers, is believed to be upregulated in cancers to prevent the apoptosis pathway.The researchers have developed novel small molecules that inhibit this protein, triggering apoptosis and cancer cell death.

Culturing More Mature iPSC-derived Cardiac Myocytes

Researchers at the University of California, Davis have developed a non-genetic, non-pharmacological method for culturing more mature induced pluripotent stem cell-derived cardiac myocytes.

  • Go to Page: